AbbVie (NYSE:ABBV) Rating Increased to Moderate Buy at Royal Bank Of Canada

AbbVie (NYSE:ABBV) was upgraded by Royal Bank Of Canada to a “moderate buy” rating in a report issued on Tuesday,Zacks.com reports.

Several other research firms have also commented on ABBV. Raymond James Financial set a $256.00 target price on AbbVie in a report on Monday, November 3rd. Scotiabank started coverage on AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective for the company. Evercore cut their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Morgan Stanley increased their price objective on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Trading Down 0.6%

ABBV stock opened at $227.01 on Tuesday. The stock’s 50 day simple moving average is $224.22 and its 200 day simple moving average is $222.70. AbbVie has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a market cap of $401.38 billion, a P/E ratio of 96.19, a P/E/G ratio of 0.79 and a beta of 0.35.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period last year, the firm posted $2.16 EPS. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts forecast that AbbVie will post 12.31 EPS for the current fiscal year.

Institutional Trading of AbbVie

Several large investors have recently made changes to their positions in ABBV. Tempo Wealth LLC acquired a new position in AbbVie during the 4th quarter worth $627,000. KW Wealth Management LLC lifted its position in shares of AbbVie by 10.0% during the 4th quarter. KW Wealth Management LLC now owns 4,573 shares of the company’s stock worth $1,045,000 after purchasing an additional 415 shares during the last quarter. MidFirst Bank bought a new stake in AbbVie during the 4th quarter valued at approximately $9,238,000. Astoria Portfolio Advisors LLC. grew its holdings in AbbVie by 60.4% in the 4th quarter. Astoria Portfolio Advisors LLC. now owns 5,092 shares of the company’s stock valued at $1,168,000 after buying an additional 1,918 shares during the last quarter. Finally, Barnes Wealth Management Group Inc lifted its holdings in shares of AbbVie by 5.3% during the fourth quarter. Barnes Wealth Management Group Inc now owns 1,337 shares of the company’s stock worth $305,000 after buying an additional 67 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $380 million investment to build two new API (active pharmaceutical ingredient) manufacturing facilities at its North Chicago campus — a multi‑year project expected to boost U.S. supply security, support production for obesity and other franchises, and create several hundred jobs (facilities targeted to be operational by 2029). AbbVie to build 2 API plants in Illinois
• Positive Sentiment: The FDA approved the VENCLEXTA (venetoclax) + acalabrutinib combination for first‑line treatment of CLL — the first all‑oral, fixed‑duration regimen for previously untreated patients, which should expand market opportunity and support oncology revenue growth. FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and a $275 price target, citing upside from operating leverage and under‑appreciated growth potential — a note that can improve sentiment among institutional investors. Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential
• Neutral Sentiment: AbbVie completed a real‑world study of Vraylar in Bipolar I disorder — supportive real‑world evidence can aid uptake, but the near‑term revenue impact is limited. AbbVie’s Real‑World Vraylar Study in Bipolar I Disorder Reaches Completion
• Neutral Sentiment: AbbVie will present at the TD Cowen Health Care Conference on March 3 — a routine investor event that could provide incremental disclosure but not guaranteed news. AbbVie to Present at the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: Multiple retail and dividend‑oriented writeups are highlighting AbbVie’s high yield and growing payout — this supports income‑investor interest but is unlikely to move the stock materially on its own. This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income
• Negative Sentiment: Analysts and research notes flag execution risk and intensifying competition across parts of AbbVie’s pipeline and immunology portfolio — these concerns are constraining upside in some models and tempering investor enthusiasm. How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative
• Negative Sentiment: Valuation and momentum considerations (ABBV trades with a high P/E and recently near its 52‑week range) plus below‑average intraday volume can prompt profit‑taking even when company news is constructive.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.